share_log

Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Surges 10%; Retail Investors Who Own 54% Shares Profited Along With Insiders

Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Surges 10%; Retail Investors Who Own 54% Shares Profited Along With Insiders

Lifecome 生物化学公司, Ltd.(深交所股票代码:002868)飙升10%;持有54%股票的散户投资者与业内人士一起获利
Simply Wall St ·  2023/05/24 18:59

Key Insights

关键见解

  • Significant control over Lifecome BiochemistryLtd by retail investors implies that the general public has more power to influence management and governance-related decisions
  • 46% of the business is held by the top 14 shareholders
  • Insiders own 33% of Lifecome BiochemistryLtd
  • 散户投资者对Lifecome BiochemistryLtd的重大控制意味着公众拥有更大的权力来影响管理和治理相关决策
  • 46% 的业务由前 14 名股东持有
  • 业内人士拥有 Lifecome BiochemistryLtd 33%

A look at the shareholders of Lifecome Biochemistry Co.,Ltd. (SZSE:002868) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 54% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

来看看 Lifecome Biometics Co. 的股东, Ltd. (SZSE: 002868) 可以告诉我们哪个集团最强大。而占据最大份额的群体是持有54%所有权的散户投资者。换句话说,该集团面临着最大的上行潜力(或下行风险)。

Following a 10% increase in the stock price last week, retail investors profited the most, but insiders who own 33% stock also stood to gain from the increase.

继上周股价上涨10%之后,散户投资者获利最多,但持有33%股票的内部人士也将从上涨中受益。

In the chart below, we zoom in on the different ownership groups of Lifecome BiochemistryLtd.

在下图中,我们放大了Lifecome BiochemistryLtd的不同所有权群体。

View our latest analysis for Lifecome BiochemistryLtd

查看我们对 Lifecome BiochemistryLtd 的最新分析

ownership-breakdown
SZSE:002868 Ownership Breakdown May 24th 2023
深交所 002868 所有权明细 2023 年 5 月 24 日

What Does The Lack Of Institutional Ownership Tell Us About Lifecome BiochemistryLtd?

关于Lifecome BiochemistryLtd,缺乏机构所有权告诉我们什么?

Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.

交易不太活跃的小公司通常缺少机构投资者,但是没有机构投资者的大公司并不常见。

There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. It is also possible that fund managers don't own the stock because they aren't convinced it will perform well. Institutional investors may not find the historic growth of the business impressive, or there might be other factors at play. You can see the past revenue performance of Lifecome BiochemistryLtd, for yourself, below.

没有机构拥有公司股份的原因可能多种多样。通常,小型的新上市公司不会引起基金经理的太多关注,因为大型基金经理不可能在公司中建立有意义的地位。基金经理也有可能不拥有这只股票,因为他们不相信该股会表现良好。机构投资者可能不会发现该业务的历史增长令人印象深刻,或者可能还有其他因素在起作用。你可以在下面亲眼看到Lifecome BioChemistryLtd过去的收入表现。

earnings-and-revenue-growth
SZSE:002868 Earnings and Revenue Growth May 24th 2023
深交所股票代码:002868 2023 年 5 月 24 日收益和收入增长

Lifecome BiochemistryLtd is not owned by hedge funds. Tan Ping Lai is currently the company's largest shareholder with 31% of shares outstanding. In comparison, the second and third largest shareholders hold about 7.2% and 5.0% of the stock. In addition, we found that Tanping Lai, the CEO has 1.0% of the shares allocated to their name.

Lifecome BiochemistryLtd不归对冲基金所有。陈平来目前是该公司的最大股东,拥有31%的已发行股份。相比之下,第二和第三大股东持有该股约7.2%和5.0%的股份。此外,我们发现首席执行官赖坦平将1.0%的股份分配给了他们的名字。

A deeper look at our ownership data shows that the top 14 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

深入研究我们的所有权数据就会发现,排名前14位的股东共持有不到一半的股份,这表明有一大批小股东没有一个股东占多数。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。我们目前没有收到分析师对该股的任何报道,因此该公司不太可能被广泛持有。

Insider Ownership Of Lifecome BiochemistryLtd

Lifecome BiochemistryLtd 的内部

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。管理层最终对董事会负责。但是,经理成为执行委员会成员的情况并不少见,尤其是当他们是创始人或首席执行官时。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。

It seems insiders own a significant proportion of Lifecome Biochemistry Co.,Ltd.. Insiders have a CN¥1.9b stake in this CN¥5.8b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

看来内部人士拥有Lifecome Biometics Co.的很大一部分股份, Ltd.。业内人士在这项58亿元人民币的业务中持有19亿元人民币的股份。很高兴看到内部人士如此投资于该业务。可能值得检查一下这些内部人士最近是否一直在买入。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a substantial 54% stake in Lifecome BiochemistryLtd, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

公众通常是个人投资者,持有Lifecome BioChemistryLtd54%的大量股份,这表明这是一只相当受欢迎的股票。这种所有权的规模赋予了来自公众的投资者一定的集体权力。它们可以而且可能确实会影响有关高管薪酬、股息政策和拟议业务收购的决策。

Private Company Ownership

私人公司所有权

We can see that Private Companies own 12%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我们可以看到,私人公司拥有12%的已发行股份。可能值得对此进行更深入的研究。如果关联方,例如内部人士,对其中一家私营公司有兴趣,则应在年度报告中披露。私营公司也可能在公司中拥有战略利益。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Lifecome BiochemistryLtd better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Lifecome BiochemistryLtd you should know about.

始终值得考虑拥有公司股份的不同群体。但是,为了更好地理解 Lifecome BiochemistryLtd,我们需要考虑许多其他因素。例如,考虑风险。每家公司都有它们,我们已经发现 Lifecome BiochemistryLtd 有两个警告信号 你应该知道。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

当然, 你可能会在其他地方找到一笔不错的投资。 所以来看看这个 免费的 有趣的公司名单。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发